Investigational drug · Phase 3
denovoSkin
Also called: EHSG-KF
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Burns.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "denovoSkin"
First trial start
2017
Oct 25, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "denovoSkin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Burns
Largest trials
Live from ClinicalTrials.gov: studies naming "denovoSkin" as an intervention, largest first.
- Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and AdolescentsPivotal-lookingRecruiting
CUTISS AGIndustry
NCT06745557 · 70 participants (planned) · Start Dec 13, 2024 · Primary completion Jun 30, 2027
Drug: denovoSkin(TM) · For: Burns
Sites: Liège, Belgium; Lyon, France; Marseille, France · 19 sites in all
CUTISS AGIndustry
NCT03394612 · 21 participants · Start Feb 14, 2018 · Primary completion Dec 1, 2023
Drug: EHSG-KF; STSG · For: Skin Wound
Sites: Naples, Italy; Padova, Italy; Amsterdam, Netherlands · 7 sites in all
CUTISS AGIndustry
NCT03227146 · 14 participants · Start Oct 25, 2017 · Primary completion Nov 30, 2022
Drug: EHSG-KF; STSG · For: Burns
Sites: Naples, Italy; Beverwijk, Netherlands; Rotterdam, Netherlands · 6 sites in all
University of ZurichAcademic, hospital or other
NCT02145130 · 12 participants · Start May 2014 · Primary completion Mar 2021
Drug: denovoDerm; denovoSkin · For: Burn Injury; Soft Tissue Injury; Skin Necrosis and 3 more
Sites: Zurich, Switzerland · 2 sites in all
- Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in ChildrenActive, not recruiting
CUTISS AGIndustry
NCT03229564 · 12 participants (planned) · Start Oct 25, 2017 · Primary completion Nov 26, 2025
Drug: EHSG-KF; STSG · For: Burns
Sites: Milan, Italy; Naples, Italy; Beverwijk, Netherlands · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Pediatric Compassionate Use of DenovoSkin, a Novel, Autologous, Engineered, Hydrogel-Based Skin Graft With Keratinocytes and Fibroblasts.
Supple M, Requena D, Mujynya K, et al. · J Burn Care Res 2026
- Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial.
Kemme FM, Pijpe A, Stoop MM, et al. · J Tissue Eng 2026
- Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in adolescent and adult burn patients: 1-year results of a prospective, randomized, controlled, multicenter phase IIB clinical trial.
Meuli M, Schiestl C, Hartmann-Fritsch F, et al. · EClinicalMedicine 2025
- Long-Term Outcomes of a Cultured Autologous Dermo-Epidermal Skin Substitute in Children: 5-Year Results of a Phase I Clinical Trial.
Schiestl C, Neuhaus K, Meuli M, et al. · J Burn Care Res 2025
- Evaluation of cultured human dermal- and dermo-epidermal substitutes focusing on extracellular matrix components: Comparison of protein and RNA analysis.
Oostendorp C, Meyer S, Sobrio M, et al. · Burns 2017
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.